Plerixafor-aided mobilization of peripheral blood hematopoietic stem cells to support subsequent high-dose chemotherapy after a prior autologous transplant

ConclusionPlerixafor proved effective to mobilize adequate numbers of PBSCs in individual patients with relapsed malignancies after prior single or tandem HDC+PBSCT. These PBSCs could establish sustained multi-lineage hematopoietic engraftment without any sequelae.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

(The Society of Thoracic Surgeons) Legendary heart-lung transplant surgeon, researcher, and professor Sir Magdi Habib Yacoub, MD, today was honored with the 2020 Earl Bakken Scientific Achievement Award from The Society of Thoracic Surgeons.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
UCLA researchers are part of an international team that reported the use of a stem cell gene therapy to treat nine people with the rare, inherited blood disease known as X-linked chronic granulomatous disease, or X-CGD. Six of those patients are now in remission and have stopped other treatments. Before now, people with X-CGD – which causes recurrent infections, prolonged hospitalizations for treatment, and a shortened lifespan – had to rely on bone marrow donations for a chance at remission.“With this gene therapy, you can use a patient’s own stem cells instead of donor cells for a transplant,&rdqu...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Publication date: Available online 27 January 2020Source: International Journal of PharmaceuticsAuthor(s): Lokesh Kaushik, Shubham Srivastava, Anshul Panjeta, Dasharath Chaudhari, Rohan Ghadi, Kaushik Kuche, Ruchi Malik, Simran Preet, Sanyog Jain, Kaisar RazaAbstractDocetaxel (DTX), a widely prescribed anticancer agent, is now associated with increased instances of multidrug resistance. Also, being a problematic BCS class IV drug, it poses challenges for the formulators. Henceforth, it was envisioned to synthesize an analogue of DTX with a biocompatible lipid, i.e., palmitic acid. The in-silico studies (molecular docking a...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 27 January 2020Source: Cancer GeneticsAuthor(s): Katsuya Yamamoto, Kimikazu Yakushijin, Mitsuhiro Ito, Hideaki Goto, Ako Higashime, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu MinamiAbstractIn multiple myeloma (MM), MYC rearrangements that result in increased MYC expression are associated with an aggressive form of MM and adverse outcome. However, the consequences of MYC amplification in MM remain unclear. Here, we describe an unusual case of plasma cell leukemia (PCL) harboring MYC amplification on double minute chromosomes (dmin). A 79-year-old woman was initially ...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
ConclusionWhile a timely work-up of advanced PC patients remains important, delays in treatment initiation due to repeated biopsies, inclusion in a clinical study or transfer to a specialized cancer center appear to be justified in light of the absence of a strong adverse effect of prolonged TTI on prognosis in advanced PC patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to evaluate the clinical outcomes, toxicity, and prognostic factors of SBRT combined with gemcitabine plus capecitabine (GEM-CAP) in treating locally advanced pancreatic cancer (LAPC).MethodsA total of 56 patients with LAPC treated with SBRT combined with GEM-CAP were reviewed from October 2010 to October 2016. The median total prescription dose at five fractions was 40  Gy (30–50 Gy). The patients were subjected to two cycles of GEM-CAP before SBRT. GEM-CAP chemotherapy was then offered for four cycles or until disease tolerance or progression. The primary endpoints included overall surviv...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAchieving pCR after neoadjuvant chemotherapy was associated with clinically meaningful improvements in survival parameters in a real-world setting. The cumulative data support pCR as a valid surrogate endpoint in both clinical trials and population-based settings.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 January 2020Source: Stem Cell ResearchAuthor(s): Chanchao Lorthongpanich, Chuti Laowtammathron, Nittaya Jiamvoraphong, Pimonwan Srisook, Pimjai Chingsuwanrote, Phatchanat Klaihmon, Nattaya Damkham, Papussorn Terbto, Supaporn Waeteekul, Yaowalak U-pratya, Surapol IssaragrisilAbstractYes-associated protein (YAP) is an important transcriptional coactivator in the Hippo signaling pathway. Using CRISPR/Cas9 technology, we established a stable YAP-knockdown (YAP-KD) induced pluripotent stem cell (iPSC) from the MUSIi012-A cell line. The YAP-KD iPSC MUSIi012-A-2 maintained the pluripotent phe...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
Authors: Somuncu ÖS, Berns HM, Sanchez JG Abstract Optogenetics have recently increased in popularity as tools to study behavior in response to the brain and how these trends relate back to a neuronal circuit. Additionally, the high demand for human cerebral tissue in research has led to the generation of a new model to investigate human brain development and disease. Human Pluripotent Stem Cells (hPSCs) have been previously used to recapitulate the development of several tissues such as intestine, stomach and liver and to model disease in a human context, recently new improvements have been made in the field ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Publication date: Available online 26 January 2020Source: Journal of Chemical NeuroanatomyAuthor(s): Sachchida Nand Rai, Payal SinghAbstractSince the discovery of L-dopa in the middle of the 20th century (1960s), there is not any neuroprotective therapy available although significant development has been made in the treatment of symptomatic Parkinson’s disease (PD). Neurological disorders like PD can be modelled in animals so as to recapitulates most of the symptoms seen in PD patients. In aging population, PD is the second most common neurodegenerative disease after Alzheimer’s disease, even though significant...
Source: Journal of Chemical Neuroanatomy - Category: Neuroscience Source Type: research
More News: Bone Cancers | Cancer & Oncology | Chemotherapy | Germ Cell Tumors | Leukemia | Lymphoma | Myeloma | Sarcomas | Stem Cell Therapy | Stem Cells | Transplants